A detailed history of Vanguard Group Inc transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Vanguard Group Inc holds 2,330,728 shares of COLL stock, worth $73.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,330,728
Previous 2,312,786 0.78%
Holding current value
$73.4 Million
Previous $71.2 Million 27.1%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$31.23 - $40.91 $560,328 - $734,007
17,942 Added 0.78%
2,330,728 $90.5 Million
Q4 2023

Feb 14, 2024

SELL
$21.16 - $30.8 $556,719 - $810,348
-26,310 Reduced 1.12%
2,312,786 $71.2 Million
Q3 2023

Nov 14, 2023

BUY
$21.23 - $24.28 $49,656 - $56,790
2,339 Added 0.1%
2,339,096 $52.3 Million
Q2 2023

Aug 14, 2023

BUY
$21.06 - $24.0 $649,006 - $739,608
30,817 Added 1.34%
2,336,757 $50.2 Million
Q1 2023

May 15, 2023

BUY
$23.0 - $29.88 $2.25 Million - $2.92 Million
97,829 Added 4.43%
2,305,940 $55.3 Million
Q4 2022

Feb 10, 2023

SELL
$16.14 - $23.55 $1.49 Million - $2.17 Million
-92,076 Reduced 4.0%
2,208,111 $51.2 Million
Q3 2022

Nov 14, 2022

BUY
$15.46 - $20.1 $398,883 - $518,600
25,801 Added 1.13%
2,300,187 $36.8 Million
Q2 2022

Aug 12, 2022

SELL
$14.22 - $20.88 $457,073 - $671,145
-32,143 Reduced 1.39%
2,274,386 $40.3 Million
Q1 2022

May 13, 2022

BUY
$17.2 - $22.5 $328,726 - $430,020
19,112 Added 0.84%
2,306,529 $47 Million
Q4 2021

Feb 14, 2022

SELL
$17.5 - $21.35 $998,637 - $1.22 Million
-57,065 Reduced 2.43%
2,287,417 $42.7 Million
Q3 2021

Nov 12, 2021

BUY
$17.75 - $25.39 $1.85 Million - $2.64 Million
104,093 Added 4.65%
2,344,482 $46.3 Million
Q2 2021

Aug 13, 2021

BUY
$21.74 - $25.28 $48.7 Million - $56.6 Million
2,240,389 New
2,240,389 $53 Million

Others Institutions Holding COLL

About COLLEGIUM PHARMACEUTICAL, INC


  • Ticker COLL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 34,126,200
  • Market Cap $1.08B
  • Description
  • Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...
More about COLL
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.